{"nodes":[{"id":"IL6R, IL6","type":"gene"},{"id":"neuroinflammation","type":"disease","has_wiki":true,"wiki_url":"/wiki/mechanisms-pd-neuroinflammation","wiki_entity":"Neuroinflammation in PD"},{"id":"PDE4A, PDE4B, PDE4D","type":"gene"}],"edges":[{"source_id":"IL6R, IL6","source_type":"gene","target_id":"neuroinflammation","target_type":"disease","relation":"promoted: IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface","evidence_strength":0.632,"evidence_sources":"[\"SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9\", \"{'claim': 'Central IL-6 trans-signaling inhibition reduces neuroinflammation and facilitates recovery from LPS-induced sickness behavior', 'pmid': '21595956'}\", \"{'claim': 'Tofacitinib (JAK inhibitor) enhances remyelination and improves myelin integrity in cuprizone-induced mice, reducing IL-6, IFN-\\u03b3, IL-1\\u03b2, and TNF-\\u03b1', 'pmid': '34618622'}\", \"{'claim': 'Oligodendrocytes drive neuroinflammation and neurodegeneration in PD via the prosaposin-GPR37-IL-6 axis', 'pmid': '39913287'}\", \"{'claim': 'sgp130 (soluble gp130) attenuates IL-6- and LPS-stimulated IL-6R activation and IL-6 protein release in microglial and neuronal cells in vitro', 'pmid': '21595956'}\"]","analysis_id":"SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9","created_at":"2026-04-13T20:58:39-07:00","edge_type":"promoted_hypothesis","source_canonical_id":"il6r,_il6","target_canonical_id":"ent-proc-f21faf77","epistemic_status":"speculative","trust_score":null,"confidence_interval":null,"trust_computed_at":null,"id":"promoted-h-2dbf5f1f","trust_confidence_low":0.3,"trust_confidence_high":0.7,"trust_computation_factors":"{}"},{"source_id":"PDE4A, PDE4B, PDE4D","source_type":"gene","target_id":"neuroinflammation","target_type":"disease","relation":"promoted: PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes","evidence_strength":0.576,"evidence_sources":"[\"SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9\", \"{'claim': 'PDE4 inhibition promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination', 'pmid': '24293318'}\", \"{'claim': 'Selective PDE4 subtype inhibition provides opportunities to intervene in neuroinflammatory hallmarks of MS', 'pmid': '36584795'}\", \"{'claim': 'GPR17 regulates oligodendrocyte survival via cAMP suppression - cAMP elevation promotes differentiation', 'pmid': '27733608'}\", \"{'claim': 'Prosaposin neuroprotection mediated by Gi-proteins and cAMP-PKA axis', 'pmid': '30260505'}\"]","analysis_id":"SDA-2026-04-13-gap-pubmed-20260410-150500-e110aab9","created_at":"2026-04-13T21:06:40-07:00","edge_type":"promoted_hypothesis","source_canonical_id":"pde4a,_pde4b,_pde4d","target_canonical_id":"ent-proc-f21faf77","epistemic_status":"speculative","trust_score":null,"confidence_interval":null,"trust_computed_at":null,"id":"promoted-h-67914e81","trust_confidence_low":0.3,"trust_confidence_high":0.7,"trust_computation_factors":"{}"}],"pagination":{"limit":5000,"offset":0,"total_edges":2,"total_nodes":3,"has_more":false}}